H.I.G. BioHealth Partners

H.I.G. BioHealth Partners is the dedicated life sciences investment arm of H.I.G. Capital, a prominent global private equity firm headquartered in Miami, Florida, with over $60 billion of capital under management. Established to specifically target the dynamic and evolving healthcare and biotechnology sectors, H.I.G. BioHealth Partners leverages the extensive resources and expertise of its parent organization to identify and support promising companies. Their investment mandate spans a broad spectrum of the life sciences landscape, including biopharmaceuticals, medical devices, diagnostics, and digital health solutions.

The firm employs a flexible investment strategy, engaging with companies across various stages of development, from nascent early-stage ventures requiring foundational capital to more mature, commercial-stage enterprises seeking growth equity or strategic partnerships. This adaptability allows them to participate in diverse opportunities within both private and public markets. H.I.G. BioHealth Partners is known for its hands-on approach, often working closely with portfolio companies to accelerate product development, navigate regulatory pathways, and scale commercial operations.

Financially, H.I.G. BioHealth Partners typically makes initial equity investments ranging from $10 million to $50 million. This substantial check size reflects their commitment to providing meaningful capital that can drive significant milestones for their portfolio companies. Furthermore, their affiliation with H.I.G. Capital provides them with the unique ability to deploy significantly larger amounts through co-investments with other H.I.G. funds, offering robust financial backing for companies with greater capital needs. Since its inception, the team has demonstrated a strong track record, having invested in over 40 companies, showcasing their deep sector expertise and consistent activity in the market.

H.I.G. BioHealth Partners stands out as a significant player in the life sciences investment arena, combining the agility of a specialized fund with the formidable financial and operational support of a global private equity powerhouse. Their strategic focus on innovation within healthcare, coupled with their flexible investment approach and substantial capital deployment capabilities, positions them as a key partner for life science companies aiming for significant growth and market impact.